Table 7.
Effect of pharmacological agents on cue-induced reinstatement of food versus drug seeking.
| Pharmacological manipulation | Food cue | Drug cue | Reference |
|---|---|---|---|
| Systemic injections | |||
| Nicotinic cholinergic antagonist | |||
| Mecamylamine | — (DC) | ↓ (nicotine) (DC) | (Liu et al., 2007) |
| D1-family antagonist | |||
| SCH 23390 or SCH 39166 | — (DS, runway) ↓ (C) | ↓ (cocaine [DS,DC,C], heroin [C], alcohol (C) | (Alleweireldt et al., 2002; Bossert e al., 2007; Hamlin et al., 2006; Hamlin et al., 2008; Hamlin et al., 2007; Weiss et al., 2001) |
| D2-family antagonist | |||
| Haloperidol | — (E) | ↓ (cocaine) (E) | (Gal and Gyertyan, 2006) |
| D3 antagonist | |||
| SB 277011-A | — (E) | ↓ (cocaine) (E) | (Gal and Gyertyan, 2006) |
| SB 277011-A | — (DS) | ↓ (cocaine) (DS) | (Cervo et al., 2007) |
| D3 partial agonist/D2 antagonist | |||
| BP-897 | — (E) | ↓ (cocaine) (E) | (Gal and Gyertyan, 2006) |
| mGluR2/3 agonists | |||
| LY379268 | ↓ (DC, DS, C) | ↓ (cocaine [DS], nicotine [C,DC], heroin [DC,C) | (Baptista et al., 2004; Bossert et al., 2005a; Bossert et al., 2004; Bossert et al., 2006; Liechti et al., 2007) |
| mGluR5 antagonist | |||
| MPEP | — (DS) | ↓ (nicotine) (DS) | (Bespalov et al., 2005) (Gass et al., 2009) |
| MTEP | — (DC) ↓ (DS) | ↓ (methamphetamine) (DC) ↓ (cocaine) (DS) | (Martin-Fardon et al., 2009) |
| mGluR1 antagonist | |||
| EMQMCM | ↓ (DS) | ↓ (nicotine) (DS) | (Dravolina et al., 2007) |
| CB1 antagonist | |||
| SR 141716a | ↓ (DC) | ↓ (cocaine, heroin, methamphetamine [DC], nicotine [DC and DS], ethanol [DS]) | (Anggadiredja et al., 2004; De Vries et al., 2005; Diergaarde et al., 2008; Economidou et al., 2006; Ward et al., 2007) |
| Preferential mu opioid antagonist | |||
| Naltrexone | — (DS) ↓ (DC) | ↓ (cocaine, alcohol) (DC, DS, C) | (Burattini et al., 2008; Burattini et al., 2006; Grimm et al., 2007) |
| Y2 agonist | |||
| Peptide YY3-36 | ↓ (DC) | — (DC) | (Ghitza et al., 2007) |
| 5-HT/1B agonist | |||
| RU 24969 | ↓ (DC) | ↓ (cocaine) (DC) | (Acosta et al., 2005) |
| 5-HT2B/2C agonist | |||
| Ro 60-0175 | — (DS) | ↓ (cocaine) (DS, C) | (Burbassi and Cervo, 2008) |
| Sigma 1 antagonist | |||
| BD1047 | ↓ (DS) | ↓ (DS) | (Martin-Fardon et al., 2007) |
| Intracranial injections | |||
| GABAa+GABAb agonists | |||
| Muscimol+baclofen | |||
| Accumbens core | ↓ (DC) | ↓ (cocaine, heroin) (DC) | (Floresco et al., 2008; Fuchs et al., 2004) |
| Accumbens shell | ↑ (DC) | — (cocaine, heroin) (DC) | (Rogers et al., 2008) |
| Lateral hypothalamus | ↓ (C) | ↓ (alcohol) (C) | (Marchant et al., 2009) |
| Non-selective inactivation | |||
| Bupivacaine or tetrodotoxin | |||
| Basolateral amygdala | ↑ (DC) | ↓(DC) | (Fuchs and See, 2002; Grimm and See, 2000; McLaughlin and Floresco, 2007) |
Abbreviations/symbols: -, not tested. DC, discrete cue; DS, discriminative stimulus cue; C, contextual cue; E, cue responding in a single extinction test; ↓, decrease; ↑, increase; -, no effect, blank space, not tested